Journal article
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, B Besse, BJ Solomon, F Blackhall, YL Wu, M Thomas, KJ O'Byrne, D Moro-Sibilot, DR Camidge, T Mok, V Hirsh, GJ Riely, S Iyer, V Tassell Show all
New England Journal of Medicine | Published : 2013
Abstract
BACKGROUND: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK ) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown. METHODS: We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen. Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or intravenous chemotherapy with either pemetrexed (500 mg per square..
View full abstractGrants
Funding Acknowledgements
Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.